Citi lowered the firm’s price target on Cytokinetics (CYTK) to $77 from $80 and keeps a Buy rating on the shares. The firm views the company’s Q2 report as largely uneventful.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Positioned for Success: Strong Financials and Strategic Advancements Drive Buy Rating
- Cytokinetics Reports Q2 2025 Financial Results and Updates
- CYTK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cytokinetics’ Strong Market Position and Growth Potential Justify Buy Rating
- Cytokinetics assumed with Market Perform from Outperform at Raymond James